Study of a new drug for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stopped taking biologic drugs like rituximab for at least 4 weeks (or 6 months for B-cell depleting ones) before starting.
- You must be on at least one but no more than two standard RA drugs like methotrexate, hydroxychloroquine, sulfasalazine, or leflunomide for at least 12 weeks, with a stable dose for the last 6 weeks.
- If you take steroids like prednisone, the dose must be low (10 mg or less per day) and stable for at least 14 days before starting.
- You must not have any active infections or serious heart problems, including a history of certain heart conditions or recent infections requiring hospitalization.
- You must have had an inadequate response or intolerance to 1 to 3 previous biologic drugs, and for some groups, have moderate to severe RA with at least 6 tender and 6 swollen joints.
- You need to have a positive blood test for rheumatoid factor or anti-CCP antibodies.
- You must not have a history of tuberculosis or certain lab abnormalities like low blood counts or liver issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.